Turkish Dermatologists' Approach For Chronic Spontaneous Urticaria: A Questionnaire Based Study
| Autor: | Atakan Nilgun, Taskapan Oktay, Erdem Teoman, Emek Kocatürk, Savk Ekin, Etikan Piril, Bulbul Baskan Emel, Koca Rafet, Utas Serap, Aktan Sebnem |
|---|---|
| Přispěvatelé: | Deri ve Zührevi Hastalıkları, Acibadem University Dspace, Zonguldak Bülent Ecevit Üniversitesi, Kocatürk, E., Piril, E., Oktay, T., Nilgun, A., Teoman, E., Serap, U., Sebnem, A., Yeditepe Üniversitesi |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Urticaria Turkish Omalizumab Disease Therapeutics Dermatology Guideline Thyroid function tests 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Quality of life Diagnosis lcsh:Dermatology medicine skin and connective tissue diseases medicine.diagnostic_test business.industry lcsh:RL1-803 language.human_language Regimen 030228 respiratory system language Methodological study business medicine.drug Dermatologists |
| Zdroj: | Dermatologica Sinica, Vol 36, Iss 2, Pp 70-74 (2018) |
| Popis: | Background/Objectives: Chronic spontaneous urticaria (CSU) is a common skin disorder which represents a challenge both for the patients and physicians. Guidelines and treatment algorithms have been created to help physicians to ease management. Our aim was to determine Turkish dermatologists' approach to CSU with regard to treatment, search for causative factors and use of instruments to assess the quality of life and severity of the disease. Methods: This was a cross-sectional methodological study which was performed by delivery of a questionnaire including ten questions about the management of CSU. Results: Analyses of 314 questionnaires revealed that the most common first-line treatments were non-sedating antihistamines in standard doses (65.6\%), while second-line treatment was updosing antihistamines (59.9\%) followed by addition of sedative-antihistamines (26.4\%) and systemic steroids (19.1\%). Third-line treatment option was omalizumab in 35\% followed by systemic steroids. Twenty-two percent of the dermatologists referred the patients to a center experienced in urticaria. Most of them were performing laboratory testing for underlying causes including thyroid function tests, C-reactive protein, thyroid auto-antibodies, stool analyses, infection markers. Urticaria activity score and chronic urticaria quality of life questionnaire were used by 30 and 13\%, respectively, while 56\% were using none of the instruments. Conclusion: Our study showed that the therapeutic management of Turkish dermatologists was parallel to the European Urticaria Guidelines. The high utility of omalizumab as a third line regimen improved patient care. Nevertheless there is a need for centers experienced in urticaria to refer anti-histamineresistant patients where third-line treatment options can not be implemented. Copyright (C) 2017, Taiwanese Dermatological Association. Published by Elsevier Taiwan LLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|